Markets
Potato Chips
Getty Images

High-priced potato chips are ticking off Americans

Standoff in aisle four.

Shoppers are no longer willing to swallow high prices for brand-name potato chips, and salty snack makers are loath to roll back the highly profitable price increases of recent years.

The result? Flatlining sales for top potato-chip brands as many buyers turn to cheaper generic options. Unit sales of potato chips were almost completely flat for the 52 weeks ending on June 28, versus the prior year. In dollar terms, sales numbers were up just over 3% — as higher prices offset the lack of growth in turnover. But that was a sharp slowdown from the previous year, when dollar sales were up almost 14% versus the prior year, according to data provided market research firm Nielsen.

If there is a bright spot in the potato-chip world, it's in the generic, or private-label, business, which has been gaining market share both in terms of sales and volumes, BofA analysts wrote in a note last month.

The potato chip buyers’ strike is deep-fried microcosm of this moment in the U.S. economy, as consumers, especially people who make less money, have grown increasingly price conscious and shifted their behavior after years of uncomfortably high price increases. Retailers and restaurant chains have reacted relatively quickly, with giants like McDonald’s, Walmart and Target all recently spotlighting a renewed focus on lowering price points.

Now, packaged food companies might be forced to take similar steps.

Prices for a 16-ounce bag of chips are up 30.6% since the end of 2020, outpacing the 20.6% increase in the consumer price index. Given that price increases for potato chips have typically been between 1%-2% a year, that’s roughly a decade to 15 years worth of price increases in around three years.

Shoppers, by and large, didn’t balk until recently. In part, analysts say, that was the result of an increase in federal spending on food support, which buttressed food spending. In 2021, the Biden administration negotiated the largest-ever increase in benefits for the Supplemental Nutrition Assistance Program, a program formerly known as food stamps.

However, those benefits began to be pared back to pre-pandemic levels in early 2023, resulting in a sales slump that has put pressure on the share prices of potato chip makers — such as Pepsico, which owns Ruffles-producer Frito Lay, Campbell’s, which makes Kettle Chips, and Pringles producer Kellanova.

So far, the companies have tried to reinvigorate demand with temporary price reductions, the type of promotions that have long been effective in nudging consumers to pick up a bag of chips. But so far, says Peter Galbo, an analyst who covers packaged food companies for BofA Securities, there’s been surprisingly little response from shoppers, suggesting prices may still be too high, and companies could be forced to cut prices back further and perhaps permanently.

"That's the conundrum for these companies,” said Peter Galbo, an analyst who covers packaged food companies for BofA Securities. “It's either, do what you've been doing — which isn't working, do nothing — which isn't a strategy, or lower prices and destroy economic profit.”

Analysts like Galbo will be keeping a close eye on what these companies say about pricing over the coming weeks — and how markets react — as they report earnings results and offer guidance about the coming year. Pepsi, which makes lots of salty snacks, is due to report numbers Thursday morning.

More Markets

See all Markets
markets

Spectrum owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its guidance for full-year revenue per user.

“It’ll be close either way in terms of whether we end up with net growth,” Fischer said.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.